Cite

HARVARD Citation

    Sprague, S. et al. (2021). A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert opinion on drug safety. 20 (12), pp. 1463-1472. [Online]. 
  
Back to record